ImmunityBio (IBRX) Announces Preliminary Financial Results for the Quarter Ended June 30

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best strong buy penny stocks to buy now. On July 25, ImmunityBio, Inc. (NASDAQ:IBRX) announced the preliminary financial results for the fiscal quarter ended June 30.

ImmunityBio (IBRX) Jumps 18% on Anktiva Access Expansion

A technician analyzing natural killer cells, as part of an immune system study and research into therapeutical agents.

The company reported a notable 60% revenue growth to $26.4 million from Q1 2025, with year-to-date sales of ~$43 million. ANKTIVA underwent a 246% unit sales volume growth in H1 2025 compared to H2 2024.

ImmunityBio, Inc. also reported $153.7 million in cash, cash equivalents, and marketable securities as of June 30.

ImmunityBio, Inc. is a clinical-stage immunotherapy company that develops next-generation therapies to treat cancer and infectious diseases. Its immunotherapy platform activates the adaptive and innate immune systems to create long-term immunological memory.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

This article is originally published at Insider Monkey.